ADHD ASRS Assessment

The Adult ADHD Self-Report Scale (ASRS) is a scientifically validated 18-item screening instrument developed by the World Health Organization (WHO) and Dr. Ronald Kessler from Harvard Medical School to identify potential attention deficit hyperactivity disorder in adults. The ASRS directly corresponds to the 18 DSM-5 diagnostic criteria for ADHD, with nine items assessing inattentive symptoms (such as difficulty organizing tasks, concentration problems, forgetfulness, and distractibility) and nine items evaluating hyperactive-impulsive symptoms (such as fidgeting, restlessness, difficulty waiting turn, and interrupting others). Each question asks how often symptoms have bothered the individual over the past six months, rated on a 5-point scale from 'never' (0) to 'very often' (4). The ASRS is divided into Part A (the first six questions) and Part B (the remaining 12 questions), with Part A representing the most predictive items for ADHD. The ASRS-6 screening version (Part A only) uses specific threshold scores for each item rather than simple summation—four or more items meeting or exceeding their specific thresholds (which vary from 2 to 4 depending on the question) indicates high likelihood of ADHD warranting comprehensive clinical evaluation. The full 18-item ASRS provides more detailed symptom assessment, with total scores helping gauge overall symptom severity. Research demonstrates the ASRS-6 has sensitivity of 68% and specificity of 99% for ADHD diagnosis, meaning it effectively identifies most adults with ADHD while minimizing false positives. The full ASRS shows internal consistency of alpha = 0.88 and correlates strongly with clinician-diagnosed ADHD. Adult ADHD affects approximately 2.5-4% of adults worldwide and often goes unrecognized because symptoms may be attributed to personality traits, stress, or other conditions. The ASRS provides accessible screening that can be completed in 5-10 minutes, facilitating identification of adults who would benefit from comprehensive ADHD evaluation.

ASRS interpretation focuses primarily on the Part A (ASRS-6) screening score, which uses a sophisticated scoring method developed through extensive research to maximize diagnostic accuracy. Part A consists of six questions specifically selected because they showed the strongest correlation with clinical ADHD diagnosis in validation studies. Each of the six Part A items has an individualized threshold: questions 1, 2, and 3 use a threshold of 'sometimes' (2 or higher), while questions 4, 5, and 6 use a threshold of 'often' (3 or higher). These varying thresholds reflect research findings that certain symptoms must occur more frequently to be clinically significant. A positive ASRS-6 screen occurs when four or more of the six Part A items meet or exceed their specific thresholds. This indicates high likelihood of ADHD and necessitates comprehensive clinical evaluation by a psychiatrist, psychologist, or other qualified professional experienced in adult ADHD diagnosis. The 99% specificity of the ASRS-6 means that positive screens are highly reliable—if you screen positive, there's a very strong probability that comprehensive evaluation will confirm ADHD diagnosis. However, the ASRS cannot by itself diagnose ADHD; clinical diagnosis requires detailed history taking, assessment of childhood symptom onset (DSM-5 requires symptoms present before age 12), evaluation of functional impairment in multiple settings (work, home, social), ruling out other explanations for symptoms, and sometimes collateral information from family members or review of school records. Part B provides additional symptom information and can be scored in multiple ways. The full 18-item total score (Part A + Part B) ranges from 0-72 and provides dimensional assessment of overall ADHD symptom severity, though no universally accepted severity cutoffs exist. Higher total scores suggest more severe or pervasive symptoms. Alternatively, inattentive symptom subscale scores (sum of nine inattentive items) and hyperactive-impulsive subscale scores (sum of nine hyperactive-impulsive items) can be calculated to identify ADHD presentation subtype—predominantly inattentive, predominantly hyperactive-impulsive, or combined presentation. If you screen positive on the ASRS, schedule evaluation within 2-4 weeks with a provider experienced in adult ADHD. Bring your completed ASRS to the appointment as it provides valuable structured information about symptom patterns. Even negative screens warrant clinical evaluation if symptoms cause significant impairment or distress, as the ASRS has 68% sensitivity meaning it misses approximately 30% of adults with ADHD.

Adult ADHD is substantially underdiagnosed, with estimates suggesting that fewer than 20% of adults with ADHD are diagnosed and treated, despite ADHD causing significant functional impairment in work, relationships, and daily life. Several factors contribute to missed diagnosis: (1) childhood diagnostic overshadowing—many adults with ADHD were never evaluated as children, particularly women, individuals with predominantly inattentive presentation without disruptive behaviors, and those with high intelligence who compensated for symptoms; (2) symptom attribution—adults and clinicians often attribute ADHD symptoms to personality traits ('I'm just disorganized'), character flaws ('I'm lazy'), stress, or other psychiatric conditions like anxiety or depression; (3) symptom evolution—ADHD symptoms change with age, with hyperactivity often manifesting as internal restlessness rather than overt physical hyperactivity in adults, making symptoms less obvious; (4) developed compensatory strategies—many intelligent adults with ADHD develop coping mechanisms that partially mask symptoms until demands exceed their compensatory capacity (such as job promotions, parenthood, or increased responsibilities); (5) co-occurring conditions—approximately 80% of adults with ADHD have at least one comorbid psychiatric condition (most commonly anxiety disorders, depression, or substance use disorders) which may be diagnosed while underlying ADHD goes unrecognized; (6) lack of provider training—many healthcare providers receive limited training in adult ADHD and may not consider it in differential diagnosis; and (7) stigma—adults may be reluctant to bring up attention or concentration concerns due to stigma about ADHD or fear of being perceived as seeking stimulant medications. The ASRS addresses several of these barriers by providing systematic, standardized screening that doesn't rely on clinician expertise in ADHD recognition. When used as part of routine mental health screening (similar to depression screening with the PHQ-9), the ASRS can identify individuals with probable ADHD who would otherwise be missed. The ASRS questions use everyday language describing common experiences rather than clinical terminology, helping individuals recognize symptoms they may have normalized or attributed to other causes. Studies show that systematic ASRS screening in primary care, mental health clinics, and substance abuse treatment programs identifies significant numbers of previously undiagnosed adults with ADHD. Early identification matters because untreated adult ADHD is associated with academic and occupational underachievement, relationship difficulties, increased risk of substance abuse, higher rates of traffic accidents and legal problems, and co-occurring anxiety and depression. Treatment with stimulant or non-stimulant medications, combined with behavioral strategies and coaching, produces substantial symptom improvement in 70-80% of adults with ADHD, with corresponding improvements in work productivity, relationship quality, and life satisfaction.

The ASRS is designed to assess ADHD symptoms specifically, but cannot definitively distinguish between ADHD and other conditions that can produce similar symptoms—this is a significant limitation that necessitates comprehensive clinical evaluation rather than relying on screening results alone. Several conditions can cause attention problems, distractibility, restlessness, or other ADHD-like symptoms: (1) anxiety disorders, where excessive worry and hyperarousal can impair concentration and cause physical restlessness, fidgeting, and difficulty sitting still; (2) major depression, which commonly causes concentration difficulties, indecisiveness, psychomotor agitation or retardation, and reduced interest in activities; (3) bipolar disorder, particularly during hypomanic or mixed episodes when racing thoughts, distractibility, and psychomotor agitation are prominent; (4) post-traumatic stress disorder (PTSD), which produces hypervigilance, concentration difficulties, restlessness, and sleep disruption; (5) substance use disorders, where stimulant use can cause agitation and hyperactivity, while withdrawal from various substances impairs concentration; (6) sleep disorders including sleep apnea, insomnia, or circadian rhythm disorders, which severely impair attention, concentration, and cause daytime fatigue and irritability; (7) thyroid disorders, particularly hyperthyroidism causing restlessness, irritability, and concentration difficulties; (8) chronic pain or other medical conditions that distract attention and impair cognitive function; and (9) medication side effects, where many medications impair concentration or cause sedation. The ASRS will likely produce elevated scores in many of these conditions because the symptoms overlap with ADHD criteria. This is why positive ASRS screens must be followed by comprehensive diagnostic evaluation that includes: detailed psychiatric history to identify co-occurring conditions; developmental history specifically assessing for ADHD symptoms in childhood (DSM-5 requires symptom onset before age 12, helping distinguish lifelong ADHD from adult-onset conditions); functional impairment assessment across multiple domains; medical history and examination to rule out medical causes; review of substance use; sleep assessment; and sometimes objective testing such as continuous performance tests, though these have limitations. Key distinguishing features support ADHD diagnosis: childhood symptom onset, chronic and pervasive symptoms across multiple settings, characteristic symptom constellation (not just isolated attention problems), and family history (ADHD is highly heritable with 70-80% genetic contribution). Importantly, ADHD commonly co-occurs with anxiety disorders (approximately 50% comorbidity), depression (approximately 30-40%), and substance use disorders (approximately 15-25%), so the presence of these conditions doesn't rule out ADHD—both may be present simultaneously and require treatment. Skilled clinicians conduct differential diagnosis considering symptom patterns, chronology, and response to prior treatments. The ASRS is valuable as a screening tool and for tracking ADHD-specific symptoms during treatment, but always requires clinical interpretation considering the broader diagnostic picture.

A positive ASRS screen (four or more Part A items meeting thresholds) indicates high probability of ADHD and should prompt referral for comprehensive diagnostic evaluation by a psychiatrist, psychologist, or other qualified mental health professional experienced in adult ADHD assessment. This evaluation typically involves multiple components conducted over one or more appointments: (1) detailed clinical interview assessing current symptoms with specific examples of how attention difficulties, impulsivity, or hyperactivity impact daily functioning in work (missing deadlines, difficulty completing tasks, job changes, underemployment), relationships (forgetting commitments, not listening, impulsivity in conversations), home (disorganization, losing items, procrastination on household tasks), and other domains; (2) developmental history establishing childhood symptom onset—DSM-5 requires several inattentive or hyperactive-impulsive symptoms present before age 12, so clinicians probe childhood school performance, report card comments, behavior problems, peer relationships, and family observations; (3) structured or semi-structured diagnostic interviews such as the Conners' Adult ADHD Diagnostic Interview or ADHD Rating Scale-IV to systematically assess DSM-5 criteria; (4) collateral information when available from parents, spouses, or others who knew the patient in childhood or observe current functioning, as individuals with ADHD may have limited insight into symptoms or may have normalized them; (5) review of historical records including school report cards, transcripts, prior psychological testing, or workplace performance evaluations providing objective documentation of difficulties; (6) assessment for co-occurring psychiatric conditions including anxiety disorders, mood disorders, substance use disorders, learning disabilities, or personality disorders using appropriate screening tools and clinical interview; (7) medical history and sometimes examination to rule out medical conditions mimicking ADHD including thyroid disorders, sleep disorders, or neurological conditions; (8) cognitive or neuropsychological testing in some cases, particularly when learning disabilities are suspected or diagnostic uncertainty exists, though such testing is not required for ADHD diagnosis and has limitations; (9) continuous performance tests (such as the Test of Variables of Attention or Conners' Continuous Performance Test) in some settings, though these have modest sensitivity and specificity and should supplement rather than replace clinical judgment; and (10) comprehensive functional impairment assessment demonstrating that symptoms cause clinically significant impairment or distress in social, academic, or occupational functioning. If ADHD diagnosis is confirmed, treatment planning involves patient education about ADHD, discussion of treatment options (stimulant medications like methylphenidate or amphetamines, non-stimulant medications like atomoxetine or guanfacine, or behavioral interventions), consideration of co-occurring condition treatment, and development of accommodations or supports. First-line treatment for adult ADHD is typically medication, with stimulants showing 70-80% response rates and effect sizes of 0.7-1.0, among the largest effects in psychiatry. Non-stimulants are alternatives for those with contraindications, substance use concerns, or stimulant side effects. Behavioral interventions including cognitive behavioral therapy adapted for ADHD, coaching, and organizational skill training provide additional benefit, particularly when combined with medication. Regular follow-up monitors treatment response using the ASRS or similar measures to track symptom improvement, assesses side effects, and adjusts treatment as needed.

The ASRS serves not only as a screening tool but also as an effective treatment monitoring instrument, allowing quantitative assessment of symptom changes with ADHD treatment. When using the ASRS for treatment monitoring, baseline assessment should occur before treatment initiation, with follow-up assessments every 4-6 weeks during treatment titration phase, then every 3-6 months during maintenance treatment. Changes in total ASRS score (sum of all 18 items) provide dimensional measurement of overall symptom improvement. While no universally accepted threshold defines treatment response for the ASRS, research suggests that a 30% reduction from baseline total score represents clinically meaningful improvement, and optimal treatment should target achieving scores in the normative range (approximately total score <24 on the 0-72 scale, though this varies by study). Some clinicians focus on Part A scores, with successful treatment ideally reducing positive Part A screening (achieving fewer than four items meeting thresholds). However, symptom-level analysis provides richer information than total scores alone. Examining individual items identifies which symptoms respond well to treatment and which remain problematic, guiding treatment adjustments. For example, if restlessness and fidgeting improve substantially with stimulant medication but organization and forgetfulness remain severely impairing, additional behavioral interventions targeting organizational skills may be needed. Stimulant medications typically produce rapid effects (within hours to days), so lack of meaningful ASRS improvement after 2-4 weeks at therapeutic doses suggests need for medication switch or dose adjustment. Non-stimulant medications (atomoxetine, guanfacine) require longer trials (6-12 weeks) before full effects manifest. Treatment response should be evaluated not just with ASRS scores but comprehensively including: functional improvement in target domains (work productivity, relationship quality, daily task completion); patient and family report of quality of life changes; adverse effect assessment; and for stimulants, monitoring of blood pressure, heart rate, weight, and sleep. Optimal ADHD treatment produces substantial symptom reduction, improved functioning, minimal side effects, and sustained benefits. Studies show that approximately 70-80% of adults with ADHD respond favorably to first or second medication trial. For those not responding adequately, consider: medication dose optimization, medication switch (between different stimulants or to non-stimulants), assessment for co-occurring conditions interfering with treatment response (such as untreated depression or substance use), evaluation of adherence barriers, or addition of behavioral interventions. Some adults with ADHD require combination treatment (such as stimulant medication during work hours plus non-stimulant medication for evening coverage, or medication plus ADHD coaching). The ASRS provides standardized, objective tracking that enhances measurement-based care approaches, helping distinguish true treatment non-response from suboptimal dosing or need for adjunctive interventions. Regular ASRS monitoring also helps detect symptom re-emergence, medication tolerance, or new functional impairments that warrant treatment adjustment.